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Abstract 
Aims 
Treatment decisions for men aged 70 years or over with localised prostate cancer need to take 
into account the risk of death from competing causes and fitness for the proposed treatment. Objective 
assessments such as those included in a comprehensive geriatric assessment (CGA) might help to 
inform the decision-making process. The aim of this study was to describe the CGA scores of a cohort 
of older men with prostate cancer, evaluate potential screening tools in this population and assess 
whether any CGA component predicts significant acute radiotherapy toxicity. 
Materials and methods 
This was a prospective cohort study undertaking pretreatment CGA, Vulnerable Elders Survey 
(VES-13) and G8 assessment in patients aged 70 years and over with localised prostate cancer planned 
to undergo radical external beam radiotherapy. 
Results 
In total, 178 participants were recruited over a 3 year period and underwent a CGA. Fifty-five 
(30.1%) participants were defined as having health needs identified by their CGA. Both VES-13 and 
G8 screening tools showed a statistically significant association with CGA needs (P < 0.001 and X2 = 
15.02, P < 0.001, respectively), but their sensitivity was disappointing. There was no association 
between a CGA (or its components) and significant acute radiotherapy toxicity. 
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Conclusions 
Many older men with localised prostate cancer are vulnerable according to a CGA. The 
screening tools evaluated were not sufficiently sensitive to identify this group. CGA outcome does not 
predict for significant acute radiotherapy toxicity. 
Key words: Comprehensive geriatric assessment; elderly; geriatric oncology; prostate cancer; 
radiotherapy tolerance; screening tests; toxicity 
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Background 
Over the last thirty years, there has been a four-fold increase in the incidence of prostate cancer 
(PC) in men aged 70 or over in England [1]. In 2010, the National Cancer Equality Initiative 
described inequalities in cancer care in the UK and identified that older people with cancer 
receive less intensive treatment than younger people [2]. In some scenarios this may be 
clinically appropriate [3,4] but when patient chronological age alone determines extent of 
intervention, there is the potential for significant under-treatment to occur [5,6,7]. There is 
considerable scope for both under- and over-treatment in the management of localised PC, 
where treatment options include radical surgery or radiotherapy; primary endocrine therapy or 
active surveillance. The decision as to which treatment approach is most appropriate for an 
individual patient depends on tumour characteristics, the risk of death from competing causes, 
fitness for the proposed treatment and patient wishes. As the population ages and a greater 
number of older patients are diagnosed with PC [8,9], such decisions will increasingly be faced.  
 
 It has been proposed that a global assessment of health termed a Comprehensive Geriatric 
Assessment (CGA) may be a useful objective measure by which to define health and predict 
risk of death from competing causes of mortality and toxicity from treatment in older patients 
with cancer [10]. A CGA assesses functional ability, co-morbidities and nutritional, cognitive, 
psychological and social status by means of a number of questionnaires. Many versions are 
available in the literature [11,12] and several studies have demonstrated their use in identifying 
vulnerable older cancer patients [13,14].  CGA may consequently have a role in predicting 
impaired tolerance and completion of oncological treatment, increased toxicity and need for 
treatment modification in this setting [15].  
 
 Once a CGA assessment is made, this result should be used as a trigger for further assessment 
and optimization of the patient to address any reversible causes. A variety of models could be 
employed including, but not limited to, referral to a specialist geriatric service. There is limited 
evidence within the cancer population regarding the impact of a CGA, subsequent intervention 
on treatment received or cancer outcomes [15]. In localised PC, where radical radiotherapy 
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typically commences after an induction period of androgen deprivation therapy, there is time to 
allow optimization of patients before making a final decision on whether a patient is suitable for 
radical radiotherapy. However, prognostic validation studies in patients with early prostate 
cancer are lacking and studies predicting tolerance of treatment are limited.  
 
 The time constraints and staff competencies of standard oncological practice make full CGA 
challenging outside of a research setting but a screening tool could be done as part of a holistic 
needs assessment; this could be a workable solution particularly if performed by a specialist 
nurse or support worker, enabling geriatric assessment for all patients. A number of screening 
tools are available [16] and we have evaluated two in this population. The VES-13 is a 13 item 
questionnaire covering age, self-rated health, limitations in physical function and functional 
disabilities. In the general geriatric population (aged 65 or over), those with a score of > 3 have 
a 4.2 times increased risk of death or functional decline over a two-year period compared with 
those with scores <3 (49.8 vs 11.8%) [17]. The G8 screening tool was developed for use in the 
cancer population and so there is no data available for its use in the general population. The G8 
covers nutritional intake, BMI, mobility, neuropsychological problems, number of medications, 
and self-rated health [18]. A score of ≤14 has been shown to predict functional decline, 
chemotherapy related toxicity and survival in several studies in solid tumours [16]. The G8 
screening tool was included in the EORTC “minimum dataset” for CGA in patients with cancer 
in 2011 [19]. 
 
In this study, we describe the distribution of CGA scores in a population of men aged 70 or over 
with a diagnosis of localised (non-metastatic) PC who are undergoing radical radiotherapy. Our 
aims were to describe the proportion of patients in whom a CGA identifies significant health 
needs, to identify if short screening tools may be an alternative to a comprehensive assessment 
in all patients and to examine if CGA scores predict significant acute radiotherapy toxicity. 
Further follow-up of this cohort will examine the role of CGA and screening tools in predicting 
functional decline in the years immediately following treatment and therefore assess whether 
they are useful in determining which patients (who appear fit on standard clinical review) might 
not derive benefit from radical treatment due to competing co-morbidities. 
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Materials and Methods 
 Study Design.  Prospective cohort study. 
 
 Participants. Inclusion criteria were men aged ≥ 70 years, diagnosed with histologically proven 
PC of any T stage and Gleason score with N0 M0 disease. All participants were planned to 
receive fractionated external beam radiotherapy with radical intent, with endocrine treatment of 
any duration permissible. Exclusion criteria were inability to give informed consent, a life 
expectancy less than three months, prior commencement or receipt of radical radiotherapy or 
prostatectomy (noting that a previous TURP was permissible). 
 
 Setting. Study recruitment occurred from December 2011 to December 2014, in outpatient 
departments at three hospital trusts in the Sussex Cancer Network, UK. All participants gave 
written informed consent for participation. The study was approved by NRES South East Coast-
Surrey (11/LO/1382) and R&D approval provided by participating trusts.  
 
Data Collection. Baseline assessments were taken within two months prior to commencement 
of radiotherapy. Patient demographics, Charlson co-morbidity index [20,21,22], body mass 
index (BMI), medications, tumour characteristics and treatment details were extracted from 
medical records. The following data were attained through a structured questionnaire via patient 
interview (by telephone or in person): WHO Performance Status (PS) (0-4), Vulnerable Elders 
Survey (VES-13) (0-13) [17,23], G8 score (0-17) [18,24], Activities of Daily Living (ADL) (0-
6) [10], Independent Activities of Daily Living (IADL) (0-8) [25], mini nutritional assessment 
(MNA) (0-14) [26], social network index (SNI) (1-4) [27], place of residence and falls in the 
preceding six months.  
 
 Follow up data were recorded at twelve weeks post completion of radiotherapy. Radiotherapy 
treatment was detailed to include dose, schedule, and start dates. 30 day mortality was checked 
prior to patient phone call. Acute bowel and genitourinary side-effects (Radiation Therapy 
Oncology Group (RTOG) graded from 0-5 [28] and treatment-related medical contacts 
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(including GP attendance and inpatient admission) were recorded from patient telephone 
interview.  
 
The primary toxicity outcome was significant acute radiotherapy toxicity, defined as RTOG 
Grade 2-5 genitourinary/bowel side-effects or acute hospital admission related to treatment, at 
any point in the twelve weeks following radiotherapy. Traditionally severe toxicity is defined as 
RTOG grade 3-5; however, grade 2 toxicity (defined as having an impact on iADLS such as 
meal preparation and simple tasks such as shopping) would constitute “significant” toxicity in 
an older population where independent functioning may be more vulnerable. This is in line with 
the recently published CHHiP trial which chose a threshold of > 2 when describing the toxicity 
experienced in a population of men receiving radical radiotherapy for PC of all ages, with a 
median age of 69 years [29].  
 
Data Analysis.  Data were analysed using the statistical package IBM SPSS Statistics. The 
distributions of the following CGA components were handled continuously: age, WHO PS, 
ADL, IADL, Charlson comorbidity score, medication number, MNA, BMI and SNI. 
Distributions of certain components were handled recognizing the following cut-offs: place of 
residence (own-home/warden-controlled/residential-home/nursing-home), cohabitation (lives 
alone/other), presence of prior falls, cognitive/psychological history (0 vs 1 vs 2), VES-13 (<3 
vs > 3), G8 (≤14 vs >14) and CGA needs (negative vs positive). 
 
 For the purposes of this study, a positive ‘CGA needs’ result was defined as a deficit in specified 
functional domains (dependence in I/ADLs (8 vs <8 and 6 vs < 6 respectively), medication 
number > 9, residence in a nursing or residential home or having fallen within the six months 
prior to assessment). This pragmatic definition includes information that would be routinely 
collected during an oncology clinic appointment, yet would raise clinical concern regarding 
fitness for intensive treatments.  
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 VES-13 scores > 3 and G8 scores ≤14 were defined as positive results for these screening tests, 
suggesting the need for a fuller CGA, in line with the published results for these tools [17,18]. 
 
 A logistic regression model was used with five input variables (age, CGA needs, MNA, PS and 
Charlson comorbidity score) with the primary outcome being significant acute radiotherapy 
toxicity. These were selected for their clinical relevance, alongside preference for continuous, 
normally distributed inputs. Other parameters not included in the composite ‘CGA need’ 
measure will further analysed when longer term outcome data is available.  
 
Sensitivity, specificity, positive and negative predictive rates for a positive ‘CGA needs’ 
outcome were calculated for the VES-13 and G8 screening tests (alongside Fisher’s exact test 
and two-sided chi-squared tests of association where appropriate). Missing values were 
accounted for within multivariate analysis and have been declared amongst the baseline results.  
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Results  
 One hundred and eighty-one participants were recruited but three were excluded owing to 
eligibility and inadequate baseline data, leaving 178 remaining participants with data to be 
analysed for distribution of CGA components. 
 
 Patient demographics, tumour characteristics and distribution of CGA components: 
Participant demographics are shown in Table 1. The median age was 74 years old (range 70-84 
years). Tumour characteristics are presented in Table 2. Median presenting PSA was 12ng/mL 
(ranging from 3 to 395ng/mL), median duration of hormone treatment prior to radiotherapy was 
six months and median total planned hormone duration was 22 months. Baseline CGA scores 
are shown in Table 3. One hundred and sixty-eight patients (94.4% of the study population) had 
sufficiently complete domains ((I)ADL, medication number, residence and falls) to calculate 
CGA needs. Of these, 55 (30.9%) were defined as having ‘CGA needs’. 46 scored on one 
domain only, five on two domains and four on three domains. Components that identified ‘CGA 
need’ were distributed across the domains: 23 due to ADL dependence, 22 to falls, 11 to IADL 
dependence, 9 to medication number and 3 to residence. 
  
 Significant acute radiotherapy toxicity: Radiotherapy toxicity data within twelve weeks post 
treatment were available for 162 patients (91.0% of the study population). One hundred and 
twenty eight (79.0%) patients experienced some acute side-effects (RTOG 1-5); 51 (31.5%) 
experienced significant acute side-effects (RTOG grade 2-5). Four (2.5%) participants 
experienced a treatment-related inpatient admission and twenty-six (16.0%) visited their GP 
regarding side effects. 53 (32.7%) participants experienced significant acute radiotherapy 
toxicity, defined as bladder or bowel toxicity (RTOG grade 2-5) or admission. There were two 
patients admitted who did not meet specific bladder and bowel toxicity criteria, yet these 
admissions were felt to be related to the more general effects of radiotherapy, including fatigue 
and interruption of normal social function which might predispose vulnerable patients to 
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concurrent illness. 
There were no deaths in the cohort at twelve weeks post radiotherapy treatment, and no patients 
stopped radiotherapy prior to completion. Ninety-six percent of radiotherapy courses were 
delivered as planned with 56.8% of patients receiving a 74Gy regime and 38.3% receiving a 
57Gy regime.   
 
 Association of CGA components with significant acute radiotherapy toxicity: There were 
133 complete observations in the logistic regression model including 44 cases of significant 
acute radiotherapy toxicity: this comprised 83% of all the cases of significant acute radiotherapy 
toxicity recorded. There was no statistically significant association between a positive CGA 
needs result and significant acute radiotherapy toxicity. Age, Charlson co-morbidity score, PS 
and MNA also did not predict this primary outcome (Table 4). 
 
Sensitivity and specificity of VES-13 and G8 compared to fuller CGA screening: 
Distribution of scores for VES-13 and G8 scores are shown in Figure 1. For cross-tabulation 
with CGA needs, there were 168 complete observations for VES-13 scores and 156 complete 
observations for G8 scores (Table 5 in appendices). Both VES-13 and G8 scoring were shown 
to have a statistically significant association with positive CGA needs ((p< 0.0001 using 
Fisher's Exact test and X2 = 15.02, p <0.0001 using Chi-squared analysis, respectively). 
 The VES-13 screening tool had 20.0% (11/55) sensitivity, 100% (113/113) specificity, 100% 
(11/11) positive predictive value and 72.0% (113/157) negative predictive value. The G8 
screening tool had 44.7% (21/47) sensitivity, 84.4% (92/109) specificity, 55.3% (21/38) positive 
predictive value and 78.0% (92/118) negative predictive value. 
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        Discussion 
 Thirty one percent of older PC patients, already clinically assessed as suitable for radical 
radiotherapy were shown to be vulnerable according to a multi-domain Comprehensive 
Geriatric Assessment. The wide distribution of scores amongst individual CGA components 
further show that the study population is heterogeneous in a range of domains, with impairment 
most frequently seen amongst ADLs, G8 scoring, medication number and social and cognitive 
function. While this population appeared “fit” on clinical assessment (with almost 95% being 
performance status 0-1), significant numbers had deficits in domains that might question the 
appropriateness of radical treatment, including ADL and IADL dependence, medication number 
and recent falls. To our knowledge, this is the first study to define a population of older men 
undergoing radical radiotherapy for localised PC in terms of a CGA, evaluate potential 
screening tools and describe its correlation with acute radiotherapy outcomes.   
 
 The degree of functional impairment demonstrated in this study is comparable to previous 
limited data in the area. In a French cohort of unselected older PC patients with variable disease 
stage, including metastatic disease, 66% showed dependence in one or more ADL, 87% were 
dependent in one of more IADL and 65% were at risk or with malnutrition [30]. Furthermore, 
6.7% risk of malnutrition in our study’s setting of localised disease is concordant with a recent 
cross sectional study, where 7.5% of those with benign prostate disease and 50% of those with 
metastatic PC were at risk of malnutrition [31]. The predominance of no/mild comorbidity 
shown in an American study of older PC patients with localised disease only, is comparable to 
70.2% of our cohort having a Charlson score of one or less [14]. This would suggest that 
comorbidity alone may not be sensitive enough to highlight potential impaired tolerance to 
treatment, as supported by recent work studying 185 older patients with colorectal cancer, 
where co-morbidity had poor predictive value for severe chemotherapy toxicity [32]. 
  
Short screening tools are likely to be more readily integrated into routine oncological care. Both 
the VES-13 and G8 have been extensively studied in variety of cancer (and non-cancer 
populations) and there is variability in their ability to predict functional decline and cancer 
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outcomes [16]. As screening tools predicting for a positive score on full CGA assessment, 
specificity has been variable, although sensitivity has been found to be high [16]. This is not in 
keeping with our findings, where both tools exhibited high specificity but relatively low 
sensitivity. This is important, both for their future use in this population, and also as a marker of 
the potential differences in our population, who had been pre-selected for radical treatment and 
therefore might be expected to be “fit”, or appear to be. It is important to note however that 
these screening tools hold value over and above their numerical “score” as they identify 
domains that may require attention. 
 
 There was no association between CGA (or its components) and significant acute radiotherapy 
toxicity. Interestingly however, the toxicity rates in this population were higher than those 
reported in the CHHiP study; 51% in our study compared to 25 and 38% (depending on 
dose/fractionation) [29]. This may support the expectation that older patients are at risk of 
increased toxicity.  Furthermore, the high rates of significant acute toxicity shown in our study 
is clinically relevant and of concern when considering treating older patients with radical 
radiotherapy. Despite this, the fact that ‘CGA needs’ did not predict for significant acute 
radiotherapy toxicity could lend support for the use of radiotherapy in an older population as 
compared to surgery, where morbidity and mortality rise with age.  
 
The significant health impairment reflected by a positive ‘CGA needs’ status in our study may 
instead be a surrogate marker for underlying, competing health issues; in time, these may render 
increased susceptibility to chronic bowel and bladder dysfunction, or have a greater impact on 
the patient’s future health than their prostate cancer, undermining the role and benefit of upfront 
radical treatment. Future results from this study will evaluate these outcomes further.   
 
Previous studies in non-cancer and non-PC populations have shown that components of the 
CGA including VES-13 and G8, can predict risk of death, functional decline and health service 
use over a two and five year timeframe period [33,34,35]. In a mixed cancer population 
including patients treated with radical and palliative intent, VES-13 had predictive value for 
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completion of radiotherapy [36] and in an analogous setting, geriatrician-led intervention based 
on CGA has been associated with improved chemotherapy tolerance in older cancer patients 
[15]. A key question which will be addressed in longer term follow up of this cohort will be 
whether these tests predict functional decline and death (including death from non-cancer 
causes) in older men with localised PC. If this is the case they may prove to be useful tools by 
which to triage patients to the different treatment options available. For example, one could 
propose a model by which those with a high risk of death from competing causes of mortality 
might be best served by active surveillance or endocrine therapy alone, rather than more radical 
approaches.  
 
The assessments used to define ‘CGA need’, which did identify 31% of this population as 
vulnerable, are not particularly onerous or specialist. The majority should be included in a first 
consultation with an oncologist, including residence and medication number; whilst much of the 
domains assessed in both ADLS and IADLS will also be covered. We propose that this level of 
assessment could in fact form an initial assessment which could be completed by a specialist 
nurse or trained support worker. In this population, all of these domains appear to be necessary 
to identify this group of potentially vulnerable patients, as 46/55 patients identified scored on 
one domain only and the domains on which patients scored were distributed across all those 
collected. Whether this definition of ‘CGA need’ predicts for chronic toxicity, functional decline 
or death remains to be seen. 
 
This population might differ from those included in many studies of CGA and screening tools in 
a number of ways. Importantly they had been pre-selected for radical treatment; we anticipate 
that those not clinically deemed suitable for radical treatment were more likely to be identified 
as vulnerable on both screening tests and a full CGA, and an unselected population might have 
approximated more closely to the populations in whom these screening tools were developed. It 
has been noted that the age threshold of this study (70 years) is lower than that sometimes used 
to define an “older adult” with cancer and that the patients were generally of good performance 
status and had little comorbidity. However, a third of patients were still vulnerable on a multi-
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domain CGA, suggesting that clinical decision-making alone does not replace a more thorough 
assessment. Performance status alone did not identify this group, or those identified as 
vulnerable using either screening test. The consequences of being in this “vulnerable” group of 
this population remain to be seen, with further data collection and analysis of longer term 
outcomes. 
 
A limitation of this study is that the pre-selected nature of this group renders a potential to 
identify over -treatment of vulnerable men but not under-treatment of those initially deemed 
unsuitable for radical radiotherapy. Furthermore there is a risk that studies of this nature recruit 
better in affluent areas, and vulnerability might be expected to be greater if the study were to be 
repeated in areas of higher social deprivation. Indeed, identifying the latter on CGA could direct 
optimization of functional status and in turn, increase treatment options available to them. 
 
In summary, many older men with localised PC, selected for radical radiotherapy, are vulnerable 
according to a CGA. Brief screening tools (VES-13 and G8) were not sufficiently sensitive in 
this population to identify those who a multi-domain CGA scored as vulnerable. A CGA did not 
identify those patients at risk of significant acute radiotherapy toxicity. Longer term follow-up 
of this cohort will identify whether a CGA predicts risk of functional decline and death from 
competing causes of mortality and thereby a means by which to select treatment options in older 
patients with localised prostate cancer. 
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